Cisplatin is a chemotherapeutic drug broadly used in the treatment of solid tumors. However, patients under this chemotherapy develop severe adverse effects, being nephrotoxicity the most frequent. Cisplatin-induced nephrotoxicity has been associated with oxidative stress, inflammation and apoptosis. Morin, a rather abundant flavonoid, presents antioxidant properties and, at the same time, decreases viability in some tumor cells. Taking into account these facts, it has been hypothesized that morin could attenuate cisplatin-induced kidney injury without interfering with antineoplastic activity of cisplatin. The aim of this study was to evaluate the potential cytoprotective effect of morin against cisplatin-induced damage in the Lilly Laboratories cell-porcine kidney 1 (LLC-PK1) cell line. In addition, the effect of pretreatment with morin on the toxicity of cisplatin on human urinary bladder transitional cell carcinoma T24 cell line was investigated. It was found that 200 µM morin attenuates cisplatin-induced damage on LLC-PK1 cells in a heme oxygenase-1 (HO-1) dependent-way. Moreover, it was found that 200 µM morin alone, decreases T24 cell viability in the same proportion as cisplatin. However, when T24 cells were pretreated with morin, the cell viability did not change compared to the cells treated only with cisplatin.
Until now, the only standard treatment to reduce cisplatin toxicity in renal cells is the active hydration with saline solution and simultaneous administration of mannitol before, during and after cisplatin treatment. Unfortunately, this regimen can also interfere with cisplatin toxicity on cancer cells [3b] . In this context, new approaches with antioxidant compounds are being investigated. Several antioxidant compounds have shown toxic effects in cancer cells while being less toxic and protective against harmful stimuli in normal cells. Jin et al. [3c] found that sulforaphane (SFN) is less toxic to cell line Medical Research Council cell strain 5 (MRC-5), derived from normal lung tissue of a 14-week-old male fetus, than to other cancer cell lines. Further, Song et al. [3d] reported that tetrahydrocurcumin induces protective effects against cisplatininduced renal damage, in Lilly Laboratories cell-porcine kidney 1 (LLC-PK1) cells and in rats. On the other hand, morin (3,5,7,2',4'-pentahydroxyflavone) is a yellow pigment, member of the flavonoids family (Scheme 1b). It can be isolated from almond, fig and more extensively from plants of the Moraceae family [4a] . The protective effects of morin against several harmful stimuli have been widely documented [4b-4d] . In some in vivo models, morin has been reported to exert a protective effect against cisplatin-induced renal damage [5a-5c] . Nevertheless, the direct effect of morin within renal proximal tubular cells has not been investigated yet. In addition, although there are evidences about the antineoplastic activity of morin, investigations on the interference of morin in cisplatin toxicity in cancer cells have not been carried out.
For these reasons the main objective of this work was to define and characterize the cytoprotective effects of morin against cisplatininduced damage in LLC-PK1 cells, a proximal tubular cell line derived from normal pig kidney. Furthermore, the possible interference of morin in the toxicity of cisplatin in T24 cells, a human bladder carcinoma cell line, was also investigated. Some polyphenols induce severe toxicity in normal cells even at low concentrations. For that reason, the effect of various concentrations of morin on viability of LLC-PK1 cells was evaluated. Results indicate that morin does not induce toxicity in LLC-PK1 cells at any of the concentrations tested (50, 75, 100 and 200 µM) ( Figure  1A ). Although cisplatin toxicity has been extensively reported in renal proximal tubular cells, in this work cisplatin effect on the viability of LLC-PK1 cells was assessed. Cisplatin decreased cell viability in all the concentrations tested (15-60 µM) ( Figure 1B Cisplatin can form adducts with several molecules within the cell, for example cisplatin-DNA interactions inhibit DNA replication, which finally conduce to cell death. Mitochondrial DNA and other mitochondrial molecules are also targets of cisplatin. Moreover, it has been shown that cisplatin causes depletion of glutathione levels, which leads to accumulation of endogenous ROS and oxidative stress [3a] . The small changes observed in attenuation of cisplatininduced cytotoxicity (by morin and other antioxidants) can be rationalized in terms of the incapacity of natural antioxidants to abrogate all cytotoxic mechanisms.
On the other hand, HO-1 is an enzyme involved in the degradation of heme, resulting in the generation of biliverdin, iron, and carbon monoxide. Several studies have reported that HO-1 is induced as a favorable response against a variety of harmful stimuli. Cisplatin toxicity has been reported to be higher in HO-1 -/-mice than in animals with the wild type phenotype [23] . It has also been reported that treatment of LLC-PK1 cells with hemin, a potent HO-1 inductor, significantly decreased ROS levels and attenuated cell death induced by cisplatin [8a] .
To investigate whether morin could increase protein levels of HO-1 antioxidant enzyme, LLC-PK1 cells were treated with 200 µM morin, evaluating several treatment times (2, 4, 6, 8, 12 and 24 h) . Protein levels of HO-1 was measured by Western blot. Morin at 200 µM significantly increased protein HO-1 expression since 8 h (Figure 3 ). To assess HO-1 levels in morin treatment previous to cisplatin exposure, cells were pretreated with 200 µM morin for 12 h and then with 30 µM cisplatin for 8 h. Levels of HO-1 were higher in cells pretreated with morin than in cells that only received Cytoprotective effect of morin against cisplatin-induced damage Natural Product Communications Vol. 13 (4) 2018 445 cisplatin (Figure 4) , so the increase in HO-1 levels induced by morin was maintained even after cisplatin treatment.
To determine whether morin-induced increase in HO-1 levels is associated with attenuation of cisplatin-induced cytotoxicity, cells were pretreated with 200 µM morin or with morin and the HO-1 inhibitor SnM321 (5, 10, and 15 µM) for 24 h and later with 30 µM cisplatin for another 24 h. Cell viability was measured by FDA assay. Results shown in Figure 5 suggest that cytoprotective effect of morin against cisplatin toxicity was mediated through HO-1 induction. To our knowledge this is the first time that such relationship has been proposed, although there are in vivo studies showing the morin capacity to attenuate cisplatin-induced cytotoxicity in renal cells [5a-5c] . When searching for compounds with cytoprotective effects against a chemotherapeutic drug, it is very important to consider the potential interference of these compounds with the antineoplastic activity of the drug. In the present study, the effects of morin alone, or in pretreatment before cisplatin administration, were evaluated on urinary bladder cells derived from transitional human carcinoma (T24). As shown in Figure 6 , 200 µM morin decreases cell viability of T24 cells in the same proportion as cisplatin. However, when the cells were pretreated with morin, an exacerbation in cell death (compared to cells incubated only with cisplatin) was not observed. This result suggests that morin induces molecular events that do not contribute to cisplatin-induced toxicity. Kuo et al. [8b] reported that morin induces G2/M arrest and apoptosis in HL-60 cells. Thus, it is possible that in T24 cells morin may also promote apoptosis and cycle cellular arrest. Taking into account that, in tumor cells, toxicity of cisplatin is almost due to inhibition of DNA replication, cells in G2/M arrest will be less susceptible to cisplatin.
Another important finding derived from the present study is that the same concentration of 200 µM morin induces cytotoxicity in T24 cells but is not toxic to LLC-PK1 cells. Moreover, it attenuates cisplatin-induced toxicity. The different action of morin in normal cells, compared to tumor cells, has already been reported. Brown et al. [8c] found that human oral squamous carcinoma cells are significantly more sensitive to growth inhibition by morin than normal oral mucosa. These authors attributed the dual action of morin, in both normal and tumor cells, to the fact that activation of AKT, a serine/threonine-specific protein kinase that plays a key role in multiple cellular processes, is inhibited at lower concentrations in carcinomas than in normal oral mucosa.
In conclusion, morin pretreatment attenuates cisplatin toxicity in LLC-PK1 cells. This effect was attributed to the capacity of morin to induce expression of HO-1 since the use of the inhibitor SnM321 abolished this effect. On the other hand, morin induces toxicity in T24 cells, in a similar way to cisplatin. Results presented here should be taken into account to continue the study of the renoprotective and anticancer properties of morin in animal models.
Experimental
Cells and reagents: T24, a urinary bladder derived from transitional human cell carcinoma, and Lilly Laboratories cell-porcine kidney (LLC-PK1) were obtained from the American Type Culture Collection (ATCC). Mouse anti-tubulin, cisplatin P4394 (cisDiamminedichloroplatinum II), morin (3,5,7,2',4'-pentahydroxyflavone), fluorescein diacetate (FDA) and 3-[4,5-dimethylthiazol-2-yl)]-2,5-diphenyl-tetrazolium bromide (MTT) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Dulbecco's Modified Eagle's Medium (DMEM), fetal bovine serum (FBS), 0.25% trypsin 1 mM EDTA and penicillin/streptomycin were purchased from GIBCO (USA). Mouse anti HO-1 spp-730 was purchased from Enzo Life Sciences, Inc. (Farmingdale, NY, USA). Fluorescent secondary antibodies anti-rabbit 800CW and anti-mouse 680RD were purchased from LI-COR (Lincoln, NE, USA). Isopropyl alcohol was purchased from J.T. Baker (Xalostoc, Edo. Mex, Mexico). HO-1 inhibitor SnM321, LY09-1701 was purchased from Frontier Sci (Logan, Utah. EUA).
Cell culture and drug treatment: LLC-PK1 and T24 cells were seeded in 48-well tissue culture microplates at 2 x 104 cells/well for 24h with DMEM supplemented with 10% FBS, 100 U/ml penicillin and 50 U/ml streptomycin in a humidified incubator with 5% CO2 atmosphere at 37oC. After 24 h of growth, LLC-PK1 cells were pretreated with 25, 50, 75, 100 and 200 µM morin for 24 h. Later cells were treated with 30 µM cisplatin for 24 h and cell viability was assayed by MTT and FDA assays. T24 cells were treated or pretreated with 75, 100 and 200 µM morin for 24 h. Later cells were treated with 100 µM cisplatin for 24 h. In this case cell viability was assayed only by the FDA technique.
Cell viability assays, MTT and FDA:
MTT is a colorimetric assay based on the dehydrogenases activity. Once in the cell, MTT is reduced to formazan by dehydrogenases and the absorbance is directly proportional to viability of cells. On the other hand, FDA is a fluorescent assay based on the esterases activity. FDA is a permeable probe that diffuses through cytoplasmic membrane, within the cell, esterases cause the cleavage of FDA and convert it in a fluorescent compound, fluorescein. Fluorescence is then directly proportional to viability of cells. After incubation with different treatments, 300 µL of MTT solution (0.33 mg/mL)/well was added and incubated for 2.5 h. The medium was aspirated and the formazan salt formed was dissolved with isopropyl alcohol. Absorbance was measured in a Synergy™ HTX multimodal reader plate (Winooski, VT, USA.) at 570 nm. For FDA assessment, 200 µL of FDA solution (12 µM)/well was added and incubated for 5 min at 37∘C in the darkness. Fluorescence was measured using a Synergy™ HTX multimodal reader plate at 488 nm and 525 nm of excitation and emission, respectively.
Western blot analysis:
For Western blot analysis of total cellular extract, LLCPK-1 cells were seeded in 100 mm petri dishes. After treatment with morin or cisplatin the cells were harvested and lysed with radio-immunoprecipitation assay (RIPA) buffer overnight at 4oC. Later, the cells were centrifuged at 12,000 g during 5 min and supernatant was collected. Bradford assay was used for protein quantifications. Protein (30 µg) was loaded in 10% acrylamide gel, separated on SDS-PAGE and transferred to nitrocellulose membrane. Membranes were blocked in 1X Tris-buffered saline, 0.1% Tween 20 (TBST) with 5% nonfat dry milk. Membranes were incubated with primary antibodies in TBS-T at 4∘C overnight and later with fluorescent secondary antibodies (anti-rabbit 800CW and anti-mouse 680RD) for 1 h in darkness. Protein bands were detected by fluorescence using Image Studio™ Lite Software LI-COR Odyssey (Lincoln, NE, USA).
Statistical analysis: All data were expressed as mean ± standard error of the mean (SEM). The statistically significant differences between control and drug treated cells were calculated by one way-ANOVA test followed by a post-hoc Bonferroni´s multiple comparisons test. These analyses were performed in GraphPad Prism version 5.03 software (San Diego, CA, USA). A p value ≤0.05 was considered statistically significant.
